Search

FOURTH GENERATION HUCART19-IL18 PRODUCES DURABLE RESPONSES IN LYMPHOMA PATIENTS PREVIOUSLY RELAPSED/REFRACTORY TO ANTI-CD19 CAR T-CELL THERAPY B Introduction: b Lymphoma (NHL) patients (pts) relapsing/refractory (R/R) to anti-CD19 chimeric antigen receptor T-cells (CART) represent a challenging group in need of effective therapies. B Conclusions: b HuCART19-IL18 therapy results in durable responses in pts with CD19+ NHL who are R/R to prior 2 SP nd sp generation anti-CD19 CART. [Extracted from the article]

B Conclusions: b In cHL patients R/R to BV and CPIs, the combination of everolimus and itacitinib was well tolerated and produced high response rates that compare favorably to historical reports of mTOR or JAK inhibitors as monotherapies. B Introduction: b Patients (pts) with classic Hodgkin lymphoma (cHL) who have failed or are intolerant of BV and CPI have few available treatment options. [Extracted from the article]

14/16 (88%) patients developed CRS; 11/14 (79%) had grade 1-2 CRS and 3 (19%) had grade 3 or greater CRS. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded per ASTCT consensus criteria. 5 (31%) patients had ICANS; 2 (12.5%) had grade 1-2 ICANS, and 3 (19%) had grade 3 or greater ICANS. [Extracted from the article]

B Introduction: b Despite recent successes with CAR T-cell therapy against CD19 in patients with B-celllymphomas, only ~30%-40% of DLBCL and FL patients maintain a durable complete long-term remission, and over half of the patients will ultimately relapse. To investigate CAR T-cell-mediated tumor killing in human cells in combination with EZH2i tazemetostat, we used the GCB-DLBCL cell lines SUDHL4 (EZH2 SP Y641F sp ), OCI-Ly18 and Toledo (WT EZH2). [Extracted from the article]

Abstract: The many features that link autoimmune disorders (AD) and lymphoma are reviewed herein. Firstly, the epidemiology indicates the increased risk of non-Hodgkin's lymphoma (NHL) development in many AD, and especially in Sjögren's syndrome, rheumatoid arthritis and systemic lupus erythematosus. In these AD, the relative risk of NHL occurrence varies between 2 and 4 up to 40 fold higher than in the general population, according to various surveys. Factors favouring or predicting NHL have been reported in detail. B-cell activation and proliferation are part of AD and are essential factors for the onset of malignant cell clones in a deregulated immunological environment. Targeting deregulated or malignant B-cells is the goal of some newly developed treatments. The prototype is anti-CD20 rituximab that has substantially modified the prognosis of B-cell NHL and is also an effective new treatment opportunity for some AD. Similarly, intensified treatments with autologous haematopoietic stem cell transplant (ASCT) that were developed for high-risk lymphoma are now under advanced investigation for use in some refractory AD. Thus, the successful use of rituximab and ASCT in both AD and NHL further emphasizes the close link between these two entities. This review provides details on the main epidemiological features regarding NHL incidence in AD, the pathogenetic factors that favour lymphoma onset and some recent advances in therapeutic approaches that are effective in both autoimmune and malignant lymphoproliferative disorders. [Copyright &y& Elsevier]